Exelogen is a biotech firm bringing relief to sufferers of raised intracranial pressure (ICP). It was co-founded by Alexandra Sinclair, a leading neuroscientist, who demonstrated (via in vitro and in vivo studies) the successful treatment of raised ICP using exenatide (a GLP-1 receptor agonist marketed as Byetta), and has orphan drug designation from the EMA and FDA. Exelogen has begun its first clinical trial, with potential for exit in 2 years.